Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 3Phase 3 2

Status

Recruiting 4Active not recruiting 4Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 2Metastatic Castration-resistant Prostate Cancer 2

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Pluvicto × Clear all
NCT05682443 2026-05-22

PRESERVE-006

OncoC4, Inc.

Phase 1/2 Active not recruiting
148 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Weill Medical College of Cornell University

Phase 1/2 Active not recruiting
50 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT05340374 2025-04-06

LuCAB

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
35 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04430192 2024-11-08

LuTectomy

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡